Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer : An Italian consensus paper and critical review
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
Triple-negative (TN) metastatic breast cancer (mBC) represents the most challenging scenario withing mBC framework, and it has been only slightly affected by the tremendous advancements in terms of drug availability and survival prolongation we have witnessed in the last years for advanced disease. However, although chemotherapy still represents the mainstay of TN mBC management, in the past years, several novel effective agents have been developed and made available in the clinical practice setting. Within this framework, a panel composed of a scientific board of 17 internationally recognized breast oncologists and 42 oncologists working within local spoke centers, addressed 26 high-priority statements, including grey areas, regarding the management of TN mBC. A structured methodology based on a modified Delphi approach to administer the survey and the Nominal Group Technique to capture perceptions and preferences on the management of TN mBC within the Italian Oncology community were adopted. The Panel produced a set of prioritized considerations/consensus statements reflecting the Panel position on diagnostic and staging approach, first-line and second-line treatments of PD-L1-positive/germline BRCA (gBRCA) wild-type, PD-L1-positive/gBRCA mutated, PD-L1-negative/gBRCA wild-type and PD-L1-negative/gBRCA mutated TN mBC. The Panel critically and comprehensively discussed the most relevant and/or unexpected results and put forward possible interpretations for statements not reaching the consensus threshold.
| Errataetall: |
ErratumIn: Cancer Treat Rev. 2023 Jun;117:102570. - PMID 37150120 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:114 |
|---|---|
| Enthalten in: |
Cancer treatment reviews - 114(2023) vom: 01. März, Seite 102511 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miglietta, F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibody-drug conjugate |
|---|
| Anmerkungen: |
Date Completed 07.03.2023 Date Revised 03.07.2023 published: Print-Electronic ErratumIn: Cancer Treat Rev. 2023 Jun;117:102570. - PMID 37150120 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ctrv.2023.102511 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351495401 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351495401 | ||
| 003 | DE-627 | ||
| 005 | 20231226051512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctrv.2023.102511 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351495401 | ||
| 035 | |a (NLM)36638600 | ||
| 035 | |a (PII)S0305-7372(23)00002-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miglietta, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer |b An Italian consensus paper and critical review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2023 | ||
| 500 | |a Date Revised 03.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Cancer Treat Rev. 2023 Jun;117:102570. - PMID 37150120 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Triple-negative (TN) metastatic breast cancer (mBC) represents the most challenging scenario withing mBC framework, and it has been only slightly affected by the tremendous advancements in terms of drug availability and survival prolongation we have witnessed in the last years for advanced disease. However, although chemotherapy still represents the mainstay of TN mBC management, in the past years, several novel effective agents have been developed and made available in the clinical practice setting. Within this framework, a panel composed of a scientific board of 17 internationally recognized breast oncologists and 42 oncologists working within local spoke centers, addressed 26 high-priority statements, including grey areas, regarding the management of TN mBC. A structured methodology based on a modified Delphi approach to administer the survey and the Nominal Group Technique to capture perceptions and preferences on the management of TN mBC within the Italian Oncology community were adopted. The Panel produced a set of prioritized considerations/consensus statements reflecting the Panel position on diagnostic and staging approach, first-line and second-line treatments of PD-L1-positive/germline BRCA (gBRCA) wild-type, PD-L1-positive/gBRCA mutated, PD-L1-negative/gBRCA wild-type and PD-L1-negative/gBRCA mutated TN mBC. The Panel critically and comprehensively discussed the most relevant and/or unexpected results and put forward possible interpretations for statements not reaching the consensus threshold | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antibody-drug conjugate | |
| 650 | 4 | |a Immune checkpoint-inhibitor | |
| 650 | 4 | |a Metastatic breast cancer | |
| 650 | 4 | |a PARP-inhibitor | |
| 650 | 4 | |a Triple-negative breast cancer | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 700 | 1 | |a Fabi, A |e verfasserin |4 aut | |
| 700 | 1 | |a Generali, D |e verfasserin |4 aut | |
| 700 | 1 | |a Dieci, M V |e verfasserin |4 aut | |
| 700 | 1 | |a Arpino, G |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchini, G |e verfasserin |4 aut | |
| 700 | 1 | |a Cinieri, S |e verfasserin |4 aut | |
| 700 | 1 | |a Conte, P F |e verfasserin |4 aut | |
| 700 | 1 | |a Curigliano, G |e verfasserin |4 aut | |
| 700 | 1 | |a De Laurentis, M |e verfasserin |4 aut | |
| 700 | 1 | |a Del Mastro, L |e verfasserin |4 aut | |
| 700 | 1 | |a De Placido, S |e verfasserin |4 aut | |
| 700 | 1 | |a Gennari, A |e verfasserin |4 aut | |
| 700 | 1 | |a Puglisi, F |e verfasserin |4 aut | |
| 700 | 1 | |a Zambelli, A |e verfasserin |4 aut | |
| 700 | 1 | |a Perrone, F |e verfasserin |4 aut | |
| 700 | 1 | |a Guarneri, V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer treatment reviews |d 1993 |g 114(2023) vom: 01. März, Seite 102511 |w (DE-627)NLM000409189 |x 1532-1967 |7 nnns |
| 773 | 1 | 8 | |g volume:114 |g year:2023 |g day:01 |g month:03 |g pages:102511 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ctrv.2023.102511 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 114 |j 2023 |b 01 |c 03 |h 102511 | ||